This cohort study used Medicare claims for enrolees with type 2 diabetes. GLP-1 RA users were propensity-matched 1:1 to users of other second-line glucose-lowering drugs, using stratified Cox regression. Aggregate psychiatric disorder risk was slightly higher (HR 1.04; 1.7 excess events per 1,000 person-years), as was depression (HR 1.11). Risks were lower for substance use disorders (HR 0.84), dementia (HR 0.87) and suicidal or self-harm events (HR 0.81). Monotherapy (HR 1.43) and escalation showed higher psychiatric risk, whereas switch and augmentation showed reduced or null risks. The aggregate increase is of uncertain clinical significance, and the monotherapy excess may reflect baseline clinical differences.
Why it is interesting: GLP-1 receptors sit in brain regions governing mood, reward and stress, yet the drugs' neuropsychiatric effects are poorly characterised. This study splits results by outcome, obesity status and treatment pattern rather than assuming one class effect.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.
Other drivers in Health today
-
Cancer
Where is cancer incidence rising and falling, what screening and new tests find earlier, and what treatment has done to survival.
13 this week -
Obesity, diabetes and GLP-1
Are obesity and diabetes still rising, what behavioural change and public policy do, and what difference do GLP-1s and other similar drugs make.
11 this week -
Heart and stroke
Whether deaths from heart disease and stroke have stopped falling, what is found earlier, what treatment and prevention do now, and what the deaths say.
6 this week -
Mental health
Deaths by suicide, the life expectancy gap in severe mental illness, and the physical disease that follows it: what mental illness costs in lives.
6 this week -
Dementia
Whether dementia is becoming more or less common, what is now found, what treatment and prevention do, and what the deaths say.
6 this week -
Frailty and multimorbidity
Whether the years added after 85 are healthy ones, how frailty and multiple conditions are measured, and where the data run out.
1 this week
